Corporate VCs are increasingly becoming a stable supplier of capital to medical device companies. Corporate investors have been participating in a growing percentage of deals being done, according to Elsevier’s Strategic Transactions, and remain focused on later-stage rounds.

START-UP's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies within the in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies sectors.

A roundup of recent medtech mergers & acquisitions, strategic alliances, and financings.

With two major exits and a third pending, the traditionally high-tech-heavy investor's new strategy is paying off. Safeguard's lower appetite for risk in the life sciences means focusing on companies with existing or near-term revenues, cash flow, and net worth being built up, rather than dependence on a regulatory or clinical milestone as an inflection point. The firm also boasts an ability to bolster the management and operational capabilities of its young companies.